Troy E. Wilson, a director at Puma Biotechnology, Inc. (NASDAQ:PBYI), executed a sale of 10,800 shares of the company's common stock on June 12, 2026. The transaction, valued at approximately $77,748, involved shares sold at varying prices between $6.98 and $7.32 per share. These sales were facilitated through a pre-arranged 10b5-1 trading plan established on March 12, 2025.
The sale comes against a backdrop of significant stock performance for Puma Biotechnology. Over the past year, the company's shares have delivered returns of 105%. Despite this strong recent performance, analysis suggests the stock may currently be trading at an undervalued level, with a price-to-earnings ratio of 14.74. The valuation metrics indicate a potential divergence between market price and fundamental earnings power, a factor often scrutinized by investors evaluating entry points in the biotechnology sector.
Earlier in the week, on June 11, 2026, Mr. Wilson acquired 27,000 shares of common stock. These shares were awarded as Restricted Stock Units (RSUs) that vest in full upon the earlier of the one-year anniversary of the grant date or the date of the annual shareholder meeting following the grant date. The vesting is contingent upon Mr. Wilson's continued service with Puma Biotechnology, aligning his long-term interests with the company's operational continuity.
Following these transactions, Mr. Wilson's direct holdings in Puma Biotechnology stand at 59,750 shares. Additionally, he maintains indirect holdings through his children, with 400 shares attributed to Child #1 and 150 shares to Child #2. This structure provides a clear view of his total beneficial ownership and the distribution of his equity stake within the organization.
The insider activity coincides with Puma Biotechnology's first-quarter 2026 earnings report, which presented challenges for the company. The firm reported an earnings per share (EPS) of -$0.04, falling short of the forecasted EPS of $0.00. Revenue for the quarter was recorded at $44.8 million, below the anticipated $49 million, resulting in a revenue surprise of -8.57%. These figures indicate a difficult quarter, with both earnings and revenue metrics missing projections.
There were no announcements regarding mergers or acquisitions in the recent updates. Analyst firms have not issued any new upgrades or downgrades for Puma Biotech during this period. The combination of insider trading activity under a 10b5-1 plan and the recent earnings miss provides a snapshot of the company's current financial standing. The pre-arranged nature of the sale suggests it was not driven by the recent earnings data, but the timing highlights the intersection of executive compensation, valuation metrics, and operational performance in the biotechnology market.